United Therapeutics EPS (Diluted) decreased by 24.0% to $5.82 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 12.2%, from $6.63 to $5.82. Over 4 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 29.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate stronger profitability even when accounting for potential share dilution.
Calculated by dividing net income by the weighted-average number of common shares outstanding, assuming the conversion o...
Used by all public companies to provide a realistic view of earnings per share for investors.
eps_diluted| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.65 | $3.42 | $2.38 | $5.03 | $2.41 | $4.91 | $2.65 | $4.86 | $5.24 | $5.38 | $4.33 | $6.17 | $5.85 | $6.39 | $6.23 | $6.63 | $6.41 | $7.16 | $7.66 | $5.82 |
| QoQ Change | — | -6.3% | -30.4% | +111.3% | -52.1% | +103.7% | -46.0% | +83.4% | +7.8% | +2.7% | -19.5% | +42.5% | -5.2% | +9.2% | -2.5% | +6.4% | -3.3% | +11.7% | +7.0% | -24.0% |
| YoY Change | — | — | — | — | -34.0% | +43.6% | +11.3% | -3.4% | +117.4% | +9.6% | +63.4% | +27.0% | +11.6% | +18.8% | +43.9% | +7.5% | +9.6% | +12.1% | +23.0% | -12.2% |